Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024
News
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth.
The NHS’ Health Research Authority (HRA) recently published its draft template Investigator Initiated Study Agreement (IIS Agreement)1 and called for comments on the draft.
According to the HRA, and in a similar way to the other model agreements used for other types of clinical trials conducted in the UK, the IIS Agreement is intended to act as a “standard contract agreement template” for use between non-commercial sponsors and commercial organisations providing support for investigator-initiated studies.
Key appointment to support continued UK and US team expansion
AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line.
The June edition of our People Pathways newsletter is now available to read here. You will find:
- One Nucleus upcoming courses
- Our new BLSA SIG on Neurodiversity
- A Blog by Tony Jones, CEO of One Nucleus
- Guest article by Aon
You can also read last month's newlsetter here.
Sandwich, Kent, UK / 26th June 2024 / Discovery Park welcomed experts in healthy ageing to its Innovation Summit on 20th June, calling for the life science network in Kent to join forces to make the county a leader in healthy ageing and longevity.
Over 230 attendees came together at the one day event to discuss innovation in healthcare, taking a close look at trends in healthy ageing, developing more integrated care, and the role of digital collaboration in future healthcare delivery.